BioScience Fact Sheet
Baxter's BioScience business continues a 60-year legacy of providing life-saving and life-sustaining specialty therapies. The products and therapies Baxter's BioScience organization produces are varied, but they share the common connection of improving the lives of patients with rare conditions, chronic diseases or limited treatment options.
Baxter continues to advance innovation in medical science by developing and improving products and therapies for patients across a range of critical care disciplines.
> Antibody therapy – Baxter is a leading provider of immunoglobulin therapies for people living with primary immunodeficiency around the world.
> Critical care therapy – Albumin is a plasma-volume expander used to treat burns and maintain adequate fluid volume in critically ill patients. Baxter is the only company to offer albumin in both flexible plastic bags and in glass containers. The flexible container weighs less, eliminates the risk of breaking and streamlines infusion set up, enabling its use in diverse conditions.
> Pulmonology therapy – For people who have reduced levels of a blood protein, alpha 1-proteinase inhibitor, Baxter provides therapies that raise these blood-protein levels. Without these, the condition can result in early-onset emphysema and premature death.
> Regenerative medicine and biosurgery – Baxter offers biological products and delivery devices used for hemostasis, tissue sealing, adhesion reduction, hard tissue regeneration, as well as soft tissue repair and microsurgery products.
> Hemophilia therapy – A leading innovator in hemophilia management, Baxter develops recombinant and plasma-based therapies for people with hemophilia.
> Vaccines – Baxter provides vaccines for seasonal and pandemic influenza, as well as meningitis C, and tick-borne encephalitis. Baxter’s Vero cell technology, used in flu vaccine production, offers potential advantages over traditional egg-based vaccine production methods.
Research & Development
Baxter’s BioScience business is supported by a robust research pipeline. The desire to improve the lives of patients drives the organization’s research and development priorities, including the development of advanced hemophilia therapies; the investigation of treatments for other bleeding disorders; uses for current therapies in the treatment of Alzheimer’s disease and multifocal motor neuropathy; novel treatments for vascular disease and tissue regeneration; and discovery and development of biosimilar products.